Biotinylated Human Siglec-9 Protein, His,Avitag™
分子别名(Synonym)
Siglec-9,SIGLEC9,CDw329,CD329
表达区间及表达系统(Source)
Biotinylated Human Siglec-9, His,Avitag (SI9-H82E9) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Gly 348 (Accession # Q9Y336-1).
Predicted N-terminus: Gln 18
蛋白结构(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 39.6 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记(Biotinylation)
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度(Biotin:Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in 25 mM MES, 150 mM NaCl, pH5.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
Siglec-9(HGMW批准的符号SIGLEC9)是属于免疫球蛋白超家族(IgSF)的唾液酸结合Ig样凝集素(siglec)家族的成员。SIGLEC9与siglec家族的许多成员显示出高度的同源性,包括siglec-7(80%)、siglec-8(72%)、siglec-5(65%)和CD33(64%)。这种高度同源性在细胞外Ig样结构域中也是保守的。它们的特征是N端的Ig样V型结构域介导唾液酸结合,随后是不同数量的Ig样C2型结构域Siglec-9具有疏水信号肽、N端Ig样V型结构域、两个Ig样C2型结构域,一个跨膜区和一个细胞质尾部。
关键字: Siglec-9;Siglec-9蛋白;Siglec-9重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。